Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA

Jens Rosenau1, Therese Kreutz, Matthias Kujawa

  • 1Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany. Rosenau.Jens@mh-hannover.de

Journal of Hepatology
|February 24, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Blind Spot in Post-Liver Transplant Care: Correlation and Causation in Immunosuppression, Drug Monitoring, and Immune Checkpoint Inhibitor-Related Rejection.

Health care science·2026
Same author

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC.

Health care science·2026
Same author

Development and Preliminary Validation of a Quality of Life Scale for Living Solid Organ Donors.

Western journal of nursing research·2026
Same author

Pediatric Organ Transplantation in China.

Pediatric transplantation·2026
Same author

Targeting NK cell CLEC12B enhances cancer immunotherapy.

Nature immunology·2026
Same author

Legal Framework on Organ Donation and Transplantation in China.

Transplantation·2026
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
Same journal

Nocturnal insulin resistance and reduced insulin availability in human MASLD.

Journal of hepatology·2026
See all related articles
This summary is machine-generated.

Hepatitis B immunoglobulin (HBIG) dosing after liver transplant depends on initial HBsAg levels, not HBV DNA. Shorter dosing intervals speed up HBsAg reduction and anti-HBs increase, aiding hepatitis B prevention.

Area of Science:

  • Hepatology
  • Immunology
  • Transplantation Medicine

Background:

  • Hepatitis B immunoglobulin (HBIG) is crucial for preventing hepatitis B virus (HBV) reinfection post-liver transplantation.
  • Current HBIG dosing protocols vary significantly across medical centers.
  • Standardizing HBIG administration requires a better understanding of its pharmacokinetic behavior.

Purpose of the Study:

  • To establish a rational basis for hepatitis B immunoglobulin (HBIG) dosing schemes after liver transplantation.
  • To investigate the kinetics of HBsAg, anti-HBs, and HBV DNA in relation to HBIG administration.
  • To determine the factors influencing the required HBIG dosage for effective hepatitis B prevention.

Main Methods:

  • Two different HBIG dosing regimens were compared in liver transplant recipients.

Related Experiment Videos

  • Group A received 10,000 IU HBIG initially, followed by daily 10,000 IU until HBsAg negativity.
  • Group B received 20,000 IU HBIG, followed by 5000 IU every 30 minutes.

    • Main Results:

    • Initial HBsAg levels strongly correlated with the HBIG dose needed to achieve HBsAg negativity (r=0.97-1.00).
    • Initial HBsAg levels also correlated with the HBIG dose required to reach anti-HBs levels above 1000 IU/l (r=0.94-1.00).
    • HBV DNA became undetectable in 7 of 11 patients and decreased significantly in the remaining four during HBIG therapy.

    Conclusions:

    • The required HBIG dose is primarily determined by pre-transplant HBsAg levels, not HBV DNA levels.
    • More frequent HBIG dosing intervals accelerate the reduction of HBsAg and the increase of anti-HBs.
    • HBIG administration leads to a rapid decrease in HBV DNA in the majority of patients.